Fulgent Genetics Inc
NASDAQ:FLGT
Fulgent Genetics Inc
Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. The company is headquartered in Temple City, California and currently employs 645 full-time employees. The company went IPO on 2016-09-28. The firm develops a technology platform, which offers a test menu. The company performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels. Its test offerings also include Solid Tumor Molecular Profiling for somatic cancer testing, Rapid Whole Genome testing developed for children in neonatal intensive care units or pediatric intensive care units its Newborn Genetic Analysis panel, and a single front-line test designed to comprehensively detect ataxia-related variants. The company also offers certain research service tests, which are ordered by research institutions and other similar institutional customers.
Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. The company is headquartered in Temple City, California and currently employs 645 full-time employees. The company went IPO on 2016-09-28. The firm develops a technology platform, which offers a test menu. The company performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels. Its test offerings also include Solid Tumor Molecular Profiling for somatic cancer testing, Rapid Whole Genome testing developed for children in neonatal intensive care units or pediatric intensive care units its Newborn Genetic Analysis panel, and a single front-line test designed to comprehensively detect ataxia-related variants. The company also offers certain research service tests, which are ordered by research institutions and other similar institutional customers.
Revenue Growth: Fulgent reported Q3 2025 revenue of $84.1 million, up from $81.8 million in Q2, with strong results in both Precision Diagnostics and Biopharma.
Margin Improvement: Gross margin rose to 42.2% (GAAP), up year-over-year due to operational efficiencies, with non-GAAP margin at 44.3%. Operating expenses declined sequentially.
Raised Guidance: The company raised full-year 2025 revenue guidance to $325 million (15% YoY growth), and now expects positive non-GAAP EPS of $0.30, up from previous loss guidance.
Product Innovation: Fulgent launched ultrarapid whole genome sequencing for NICU and expanded its Beacon carrier screening panel to 1,000 genes, maintaining a market lead.
Therapeutics Progress: Clinical candidate FID-007 showed strong Phase II preliminary results, with continued enrollment and a platform expansion. FID-022 advanced to Phase I.
Cash Position: The company ended the quarter with $787.7 million in cash, expecting to finish 2025 with about $800 million, assuming planned tax refunds arrive.
